1186635-75-5

Upstream product

• 917-64-6 methyl magnesium iodide 
• 1186635-73-3 ethyl 4-(2-(5-amino-8-methylbenzo[f][1,7]naphthyridin-2-yl)ethyl)benzoate 
• 1186638-03-8 ethyl 4-((5-amino-8-methylbenzo[f][1,7]naphthyridin-2-yl)ethynyl)benzoate 
• 1186638-02-7 ethyl 4-((5-chloro-6-cyanopyridin-3-yl)ethynyl)benzoate 
• 10602-03-6 ethyl 4-ethynylbenzoate 
• 1150561-75-3 tert-butyl 5-methyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenylcarbamate 
• 1186637-29-5 tert-butyl (2-bromo-5-methylphenyl)carbamate 
• 53078-85-6 2-bromo-5-methylaniline 
• 85331-33-5 2-Cyano-3,5-dichloropyridine 

Relevant academic research and scientific papers

Homogenous suspension of immunopotentiating compounds and uses thereof

The present invention generally relates to homogeneous suspensions of small molecule immune potentiators (SMIPs) that are capable of stimulating or modulating an immune response in a subject in need thereof. The homogeneous suspensions may be used in combinations with various antigens or adjuvants for vaccine therapies.

COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS

The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with Toll-Like Receptors, including TLR7 and TLR8. In one aspect, the compounds are useful as adjuvants for enhancing the effectiveness of a vaccine (formula I) wherein: X3 is N; X4 is N Or CR3; X5 is -CR4=CR5.